Life ScienceCompany
Assertio has acquired 4 companies, including 3 in the last 5 years. It has also divested 3 assets.
Assertio’s largest acquisition to date was in 2023, when it acquired Spectrum Pharmaceuticals for $248M. It’s largest disclosed sale occurred in 2020, when it sold Assertio Therapeutics - NUCYNTA to Collegium Pharmaceutical for $375M. Assertio has acquired in 4 different US states. The Company’s most targeted sectors include life science (75%) and medical products (25%).
Join Mergr and gain access to Assertio’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
M&A Summary
-
M&A Total Activity7
- M&A Buy Activity4
- M&A Sell Activity3
- Total Sectors Invested 2
- Total Countries Invested 1
- M&A Buy/Sell Connections 5
- M&A Advisors 6
Unlimited Searches
